Pharmacia & Upjohn regulatory update

Pharmacia & Upjohn submitted an NDA to the FDA for Pramipexole, a dopamine agonist to treat the signs and symptoms of Parkinson's disease. Pharmacia & Upjohn said it believes Pramipexole can be used as a monotherapy at the early stages of disease. Currently available dopamine agonists are approved for adjunctive treatment with levodopa at later stages of the disorder. ...